Endothelin News and Research

RSS

Endothelins are proteins that constrict blood vessels and raise blood pressure. They are normally kept in balance by other mechanisms, but when they are over-expressed, they contribute to high blood pressure (hypertension) and heart disease.

Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma, Inc., a privatively held biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare diseases, announced today that its lead compound tacrolimus (SPI-026) has been granted Orphan Drug Designation by the U.S. Food & Drug Administration for the treatment of pulmonary arterial hypertension (PAH).

18 Mar 2015

UT Southwestern neuroscientists identify key brain cells that control circadian rhythms

UT Southwestern Medical Center neuroscientists have identified key cells within the brain that are critical for determining circadian rhythms, the 24-hour processes that control sleep and wake cycles, as well as other important body functions such as hormone production, metabolism, and blood pressure.

18 Mar 2015

Endothelin gene expression linked to vision loss in premature babies

A gene known to play a major role in constricting blood vessels also appears to be a major player in the aberrant blood vessel growth that can destroy the vision of premature babies.

11 Nov 2014

Vascular receptor autoantibodies implicated in SSc-PAH

medwireNews: Autoantibodies to endothelin receptor type A and angiotensin receptor type-1 predict the development of, and mortality from, systemic sclerosis-associated pulmonary arterial hypertension, research suggests.

22 Oct 2014

Targeted treatments may improve idiopathic PAH survival

Patients with idiopathic pulmonary arterial hypertension may live longer if they are given targeted treatments than if they receive conventional management, researchers suggest.

29 Sep 2014

CHEST guideline released for PAH

An updated CHEST guideline for treating pulmonary arterial hypertension provides some evidence-based recommendations but also highlights many evidence gaps.

15 Jul 2014

Olive oil supplements may counteract adverse cardiovascular effects of exposure to air pollution

Taking olive oil supplements may counteract some of the adverse cardiovascular effects of exposure to air pollution, according to a new study presented at the 2014 American Thoracic Society International Conference.

20 May 2014

Olive oil supplements may counteract adverse cardiovascular effects of air pollution

19 May 2014

Ambrisentan cleared for use with phenprocoumon

Starting treatment with ambrisentan does not necessitate adjusting the dose of the oral anticoagulant phenprocoumon in patients with pulmonary hypertension who require both medications, report researchers.

7 May 2014

Meta-analysis links signalling pathways to bipolar disorder

A meta-analysis of genome-wide association studies has identified six biological pathways that may be involved in the genetic predisposition to develop bipolar disorder.

23 Apr 2014

Bayer’s Adempas now available in the UK to treat patients with CTEPH

Adempas (riociguat) is available in the UK today as the first drug treatment for CTEPH, to treat adult patients with WHO Functional Class (FC) II to III with inoperable or persistent disease to improve exercise capacity.

1 Apr 2014

ATS develops clinical practice guidelines to help clinicians identify, manage patients with sickle cell disease

The American Thoracic Society has developed clinical practice guidelines to help clinicians identify and manage patients with sickle cell disease who are at increased risk for mortality from pulmonary hypertension.

18 Mar 2014

New research uncovers abnormal molecular signaling pathways for kidney failure

Prevention and reversal of chronic kidney disease is an urgent public health need. The disease affects 1 in 10 Americans, is debilitating and deadly, and existing drugs, at best, offer only mild delay in progression to end-stage kidney failure.

4 Mar 2014

Researchers identify protein that promotes growth of brain cells damaged by MS

Vittorio Gallo, PhD, Director of the Center for Neuroscience Research at Children's National Health System, and other researchers have found a "potentially novel therapeutic target" to reduce the rate of deterioration and to promote growth of brain cells damaged by multiple sclerosis (MS). Current therapies can be effective in patients with relapsing MS, but have little impact in promoting tissue growth.

9 Feb 2014

Novel IRL-1620 compound may be useful in treating Alzheimer's disease

The novel compound IRL-1620 may be useful in treating Alzheimer's disease as it has been shown to prevent cognitive impairment and oxidative stress in animal models. This research is being presented at the 2013 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in San Antonio, Nov. 10-14.

14 Nov 2013

Opsumit drug receives FDA approval to treat adults with pulmonary arterial hypertension

The U.S. Food and Drug Administration today approved Opsumit (macitentan), a new drug to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or the need for lung transplantation.

19 Oct 2013

Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare announced today that the United States Food and Drug Administration has approved Adempas (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and (ii) the treatment of adults with pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity, improve WHO functional class and delay clinical worsening.

9 Oct 2013

Intracerebral injection of BSC may reduce post-stroke cognitive dysfunction

27 Aug 2013

BSCs may offer new approach for reducing post-stroke cognitive dysfunction

Cognitive deficits following ischemic stroke are common and debilitating, even in the relatively few patients who are treated expeditiously so that clots are removed or dissolved rapidly and cerebral blood flow restored. A new study in Restorative Neurology and Neuroscience demonstrates that intracerebral injection of bone-marrow-derived mesenchymal stem cells reduces cognitive deficits produced by temporary occlusion of cerebral blood vessels in a rat model of stroke, suggesting that BSCs may offer a new approach for reducing post-stroke cognitive dysfunction.

26 Aug 2013

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.

21 May 2013